Tivic secures NIAID agreement for Entolimod radiation syndrome studies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Tivic Secures NIAID Non-Clinical Evaluation Agreement for Entolimod, Targeting Gastrointestinal Acute Radiation Syndrome
March 26, 2026 8:31 AM EDTArmed Forces Radiobiology Research Institute (AFRRI) Will Conduct the Gastrointestinal Acute Radiation Syndrome (GI-ARS) Study
SAN ANTONIO, TX / ACCESS Newswire / March 26, 2026 / Tivic Health Systems Inc. (Nasdaq: TIVC), a clinical-stage immunotherapeutics company, today announced it has entered into an agreement with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to sponsor and conduct a series of preclinical studies evaluating Entolimod for gastrointestinal acute radiation syndrome (GI-ARS).
The program is expected to support... More
